23 July 2026

Fevara plc

("Fevara", the "Company", or the "Group")

Result of Annual General Meeting 2026 - Update Statement

Fevara plc (LSE: FVA), the international specialist in livestock supplements, provides the following update in accordance with Provision 4 of the UK Corporate Governance Code in respect of the shareholder vote against at the Company's Annual General Meeting ("AGM") held on 11 February 2026.

As announced on 12 February 2026, all resolutions were duly passed at the AGM. However, the Board noted that Resolution 6, regarding the re-election of Gillian Watson as a Non-Executive Director, received 39.26% of votes against.

Following the AGM, the Company undertook engagement with a limited number of shareholders, including certain shareholders who voted against the resolution, to understand the reasons for the dissent. Despite limited response from the shareholders approached, the Board believes that the principal concern related to Ms Watson's being unable to attend two late scheduled Board meetings during the financial year.  The Board believes that, while the absences are always regrettable, they do not give rise to any concerns regarding Ms Watson's overall commitment or effectiveness, and that she continues to make a valuable contribution to the Board.

The Board remains committed to maintaining an open and constructive dialogue with shareholders and will continue to engage, where appropriate, on governance matters. Further disclosure will be provided in the Company's next Annual Report.

Enquiries:

About Fevara plc:

Fevara is an international specialist in livestock supplements.

Fevara's purpose is to empower farmers in extensive grazing systems with research-proven products that boost profitability, improve resource efficiency and support sustainable agriculture.  The Group develops, manufactures and markets research-proven supplements, including feed licks, blocks, bagged minerals, and boluses for cattle, sheep and horses, sold under recognised and trusted brands, including Crystalyx^®, HorsLic^®_, Horslyx^®, Scotmin Nutrition^®, SmartLic^® and Tracesure® Advanced.

Headquartered in Carlisle, Cumbria, in the UK, Fevara has five manufacturing sites in the UK, US and Brazil with three operational joint ventures in Germany and the US. It serves customers in more than 20 countries through its expansive international distribution and support network.

Fevara has been listed on the London Stock Exchange since 1972.

For more information, visit: www.fevara.com